Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0451
Trial ID NCT03642496
Disease B-Cell Malignancy
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment ET019002-T
PhaseEarly_Phase1
Recruitment statusUnknown
TitleThe Clinical Study of Structurally Optimized ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
Year2018
CountryChina
Company sponsorFirst Affiliated Hospital Xi'an Jiaotong University
Other ID(s)XJTU1AF2018LSL-C003
Vector information
Vectorlentivirus
Transgene/Inserted genehuman TCR γ constant chain (UniProtKB-P0CF51); human TCR δ constant chain (UniProtKB-B7Z8K6); scFv of ET190L1; scFv of ET190L1
Viral genome modificationET190L1-TCR fuses the Fab fragment of ET190L1 with the C-terminal signaling domain of a γ/δ TCR, which is derived from the human TCR γ constant chain (UniProtKB-P0CF51) and δ constant chain (UniProtKB-B7Z8K6). The heavy chain domain of the Fab fragment is fused to the δ chain, and the light chain domain is fused to the γ chain. Moreover, an independent chimeric molecule consisting of the scFv of ET190L1 and the CD28 transmembrane and intracellular domain is added to further promote T cell activation.
Vector production methodThe ET190L1-TCR and the scFv/CD28 co-stimulatory molecule sequences were cloned into a pCDH lentiviral vector (Systems Biosciences, California, USA) for generation of ET019003 cells.

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 0.75E6 cells/kg, 1.5E6 cells/kg, 3E6 cells/kg
Donor type Autologous
Pts 18
Age Child, Adult, Older_Adult
Outcome 6/12(CR); 4/12(PR)
Adverse reactions 1(ICANS)
References PMID: 35776199

Relationship Graph

Overview of Knowledge Graph